How Analysts Rated Vical Incorporated (NASDAQ:VICL) Last Week?

January 10, 2018 - By Vivian Park

 How Analysts Rated Vical Incorporated (NASDAQ:VICL) Last Week?

Vical Incorporated (NASDAQ:VICL) Ratings Coverage

Among 2 analysts covering Vical (NASDAQ:VICL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vical had 5 analyst reports since July 19, 2016 according to SRatingsIntel. The rating was reinitiated by H.C. Wainwright with “Buy” on Tuesday, July 19. The rating was maintained by H.C. Wainwright on Tuesday, November 21 with “Buy”. As per Monday, June 12, the company rating was reinitiated by Rodman \u0026 Renshaw. The rating was maintained by H.C. Wainwright with “Buy” on Monday, June 12. H.C. Wainwright maintained the shares of VICL in report on Wednesday, August 9 with “Buy” rating. Below is a list of Vical Incorporated (NASDAQ:VICL) latest ratings and price target changes.

21/11/2017 Broker: H.C. Wainwright Rating: Buy Maintain
09/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.0000 Maintain

The stock increased 0.55% or $0.01 during the last trading session, reaching $1.84. About 34,134 shares traded. Vical Incorporated (NASDAQ:VICL) has declined 38.65% since January 10, 2017 and is downtrending. It has underperformed by 55.35% the S&P500.

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company has market cap of $34.22 million. It is developing various DNA vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 that is in Phase II clinical trial to prevent and protect against lesion recurrence; VL-2397 antifungal program, which is in Phase I clinical trial for the treatment of invasive fungal infections; and CyMVectin prophylactic vaccine for CMV that is in preclinical stage for the prevention of fetal transmission during pregnancy. It currently has negative earnings. The firm also engages in contract manufacturing of plasmid investigational products for various clients.

More notable recent Vical Incorporated (NASDAQ:VICL) news were published by: Globenewswire.com which released: “Vical Highlights Successful Outcome of Phase 1 Trial of VL-2397 Novel …” on May 02, 2017, also Seekingalpha.com with their article: “Vical Incorporated’s (VICL) CEO Vijay Samant on Q2 2017 Results – Earnings …” published on August 08, 2017, Seekingalpha.com published: “What’s Up With Vical’s Allovectin-7 Phase III Trial?” on July 02, 2012. More interesting news about Vical Incorporated (NASDAQ:VICL) were released by: Globenewswire.com and their article: “Vical Announces Completion of the Phase 3 ASP0113 CMV Vaccine Trial” published on October 10, 2017 as well as Globenewswire.com‘s news article titled: “Vical to Host Virtual Research & Development Day on May 2, 2017” with publication date: April 24, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.